In most metastatic cancers KAI1 expression is frequently down-regulated and it has recently been proposed that CD82 could be a promising biomarker for the prognosis of patients with malignant neoplasms (Malik et al., 2009) and for predicting the metastatic potential of several human cancers, including breast cancer (Steeg et al., 2003; (Zhong et al., 2016). Here, CD82 is linked to breast carcinoma.